New multicentric studies in hypertension;Nuevos estudios multicéntricos en hipertensión arterial

Revista Medica de Chile

Volumn 126, Issue 10, 1998, Pages 1238-1246

  Román A, Oscar ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b NONE   (Chile)

Author keywords

Antihypertensive agents; Hypertension; Mortality; Multicenter trials

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HYPERTENSION; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0032174489     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. ROBERTSON JIS. The large studies in hypertension: what have they shown? Br J Clin Pharmac 1987; 24: 3S-14S.
2. Australian therapeutic trial in mild hypertension. Report by the management committee. Lancet 1980; i: 1261-7.
3. ISLES CG, WALKER L, BEEVERS DG. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertension 1986; 4: 141-56.
4. VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP. Effects of treatment on morbidity in hypertension. II. Results in patients with distolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-52.
5. HELGELAND A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo Study. Am J Med. 1980; 69: 725-32.
6. MEDICAL RESEARCH COUNCIL WORKING PARTY. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
7. MULTIPLE RISK FACTOR INTERVENTION TRIAL RESEARCH GROUP. Multiple risk factor intervention trial: risk factors changes and mortality results. JAMA 1982; 248: 1465-77.
8. SAMUELSSON O, WILHELMSEN L, ANDERSSON OK, PENNERT K, BERGLUND G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA 1987; 258: 1768-76.
9. MEDICAL RESEARCH COUNCIL WORKING PARTY. Adverse reactions to bendrofluazide and propranolol following treatment of mild hypertension. Lancet 1981; ii: 539-43.
10. The International Prospective Primary Prevention Study on Hypertension. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol. J Hypertension 1985; 3: 379-92.
11. AMES RP, HILL P. Elevation of serum lipids levels during diuretic therapy of hypertension. Am J Med 1976; 61: 748-57.
12. ROMAN O, PINO ME, VALENZUELA MA. Effects of pindolol and clopamide on blood lipids in arterial hypertensive patients. Cardiology 1987; 74: 219-25.
13. Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S18-S25.
14. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73.
15. HANSSON L. Shortcomings of current antihypertensive therapy. Am J Hypertension 1991; 4: 84S-87S.
16. FLECKENSTEIN A. CALCIUM ANTAGONISM IN HEART AND SMOOTH MUSCLE. 1983 J Wiley & Sons Ed. NY.
17. OPIE LH. ANGIOTENSIN CONVERTING ENZYME INHIBITORS: SCIENTIFIC BASIS FOR CLINICAL USE. 1992 J Wiley & Sons Ed. NY.
18. TORVIK D, MADSBU HP. Multicenter 12-week double blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986; 21: 69S-75S.
19. GODFRAIND T. Classification of calcium antagonists. Am J Cardiol 1987; 59: 11B-23B.
20. WILLIAMS GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517-25.
21. THE JOINT NATIONAL COMMITTEE ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD PRESSURE. The fifth report (JNC V). Arch Intern Med 1993; 153: 154-83.
22. WEBER MA. Hypertension: steps forward and steps backward: the Joint National Committee Fifth Report. Arch Intern Med 1993; 153: 149-52.
23. LICHTLEN P, HUGENHOLTZ P, RAFFLENBEUL W, HECKER H, JOST S, DECKERS J. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109-13.
24. LICHTLEN PR, LIPPOLT P, RAFFLENBEUL W, ON BEHALF OF THE INTACT GROUP INVESTIGATORS. Retardation of angiographic progression of coronary artery disease by nifedipine: the 6-year follow-up study of INTACT (International Nifedipine Trial on Antiatherosclerotic Therapy). J Cardiovasc Pharmacol 1996; 28: S10-S21.
25. DAHLOF B, PENNERT K, HANSSON L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
26. BJORK S, NYBERG G, MULOC N, GRANERUS G, HERLITZ N, DURREL M. Beneficial effects of ACE inhibition on renal function in patients with diabetic nephropathy. BJM 1986, 293: 471-4.
27. LINZ W, SCHAFER J, WIEMER G, ALBUS U, SCHOLKENS BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmac 1992; 107: 970-5.
28. ABERG G, FERRER P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S65-S72.
29. CAPTOPRIL MULTICENTER RESEARCH GROUP. A placebo-controlled trial of captopril in refractory congestive heart failure. JACC 1983; 2: 755-63.
30. LITHELL HO, POLLARE T, BERNE C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other hypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S46-S52.
31. MINISTERIO DE SALUD CHILE. Departamento Salud de las Personas. Resultado de la evaluación del Programa de Salud Cardiovascular. Años 1992-94-96.
32. 1988 JOINT NATIONAL COMMITTEE. The 1988 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023-38.
33. DAHLOF B, LINDHOLM LH, HANSSON L, SCHERSTEN B, EKBOM T, WESTER PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
34. AMERY A, BIRKENHAGER W, BRIXKO P, BULPITT C, CLẼ MENT D, DERUYTTERE M ET AL. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349-55.
35. SHEP COOPERATIVE RESEARCH GROUP. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results ofthe Systolic Hypertension in Elderly Program. JAMA 1991; 265: 3255-64.
36. WENGER NK. Inclusion of elderly individuals in clinical trials. Cardiovascular disease and cardiovascular therapy as a model. 1993 Proceedings of a workshop. Marion Merrel Dow Inc. Kansas City.
37. STAMLER J, STAMLER R, NEATON J. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615.
38. FASCE E. Hipertensión arterial 1995. Ed. Universidad de Conception Facultad de Ciencias Biológicas. Concepción.
39. NEATON JD, GRIMM RH, PRINEAS RJ, STAMLER J, GRANDITS JA, ELMER PJ ET AL. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA 1993; 270: 713-24.
40. KOSTIS JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular disfunction. Am J Hypertension 1995; 8: 908-14.
41. THE SOLVD INVESTIGATORS. Studies of left ventricular dysfunction (SOLVD). Rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Carcliol 1990; 66: 315-22.
42. LANSHENG G, ZHANG, W, ZHU Y, ZHU J, KONG D, PAGE V ET AL. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237-45.
43. ROMAN O, CUMSILLE F, GENET W. Análisis estadístico de sobrevivencia de pacientes usando el modelo de riesgos proporcionales de Cox. Tesis Escuela de Salud Pública. Facultad de Medicina. U de Chile 1990. Santiago. Chile.
44. HANSSON L, ZANCHETTI A, FOR THE HOT STUDY GROUP. The Hypertension Optimal Treatment (HOT) Study. Patients characteristics: randomization, risk profiles and early blood pressure results. Blood Pressure 1994; 3: 322-7.
45. PSATY BM, SMITH NL, SISCOVICK DS, KOEPSELL TD, WEISS NS, HECKBERT SR ET AL. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-45.
46. WELIN L, ELVELIN L, NIKLASSON A, LERNFELDT B. Overview of the safety of felodipine based on clinical trials in patients with hypertension. Am J Cardiol 1997; 79: 996-9.
47. MCMAHON S, PETO R, CUTLER J, COLLINS R, SORLIE P, NEATON J ET AL. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression, dilution bias. Lancet 1990; 335: 765-74.
48. COLLINS R, PETO R, MACMAHON S, HERBERT P, FIEBACH NH, EBERTEIN KA ET AL. Blood pressure, stroke and coronary artery disease. 2. Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335: 827-38.
49. CRUISHANK JM, THORPE JM, ZACHARIAS FG. Benefits and potential harm of lowering high blood pressure. Lancet 1987; i: 581-4.
50. ROMAN O. ¿A qué niveles bajar la presión arterial en la hipertensión esencial para optimizar el resultado? Rev Méd Chile 1995; 123: 1037-40.
51. ALDERMAN MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-35.
52. ROMÁN O, MEZA N. Arterial hypertension. End organ damage and its prevention. Intercontinental Cardiol 1996; 5: 49-56.
53. WHELTON PK, HE G, CUTLER JA, BRANCATI FL, APPEL LJ, FOLLMAN D ET AL. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-32.
54. VALDÉS G, VIO CP, MONTERO J, AVENDAÑO R. Potassium suplementation lowers blood pressure and increases urinary kallikrein in essential hypertension. J Human Hypertens 1991; 5: 91-6.
55. MIDGLEY JP, MATHEW AG, GREENWOOD CM, LOGAN AG. Effect of reduced dietary sodium on blood pressure, a meta-analysis of randomized controlled trials. JAMA 1996; 275: 1590-97.
56. ALLENDER PS, CUTLER JA, FOLLMANN D, CAPPUCCIO FP, PRYER J, ELLIOT P. Dietary calcium and blood pressure: a metaanalysis of randomized clinical trials. Ann Intern Med 1996; 124: 825-31.
57. SCHMIEDER RE, MARTUS P, KLINGBEIL A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
58. BUCHER HC, GUYATT GH, COOK RJ, HATALA R, COOK DJ, LANG GD ET AL. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia. JAMA 1996; 275: 1113-17.
59. THE TRIALS OF HYPERTENSION COLLABORATIVE RESEARCH GROUP. Effects of weight loss and sodium reduction intervention on blood pressure incidence in overweight people with high normal blood pressure. Arch Intern Med 1997; 157: 657-67.
60. FURBERG CD, PSATY BM, MEYER JV. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
61. AD HOC SUBCOMMITTEE OF THE LIAISON COMMITTEE OF THE WORLD HEALTH ORGANIZATION AND THE INTERNATIONAL SOCIETY OF HYPERTENSION. Effects of calcium antagonists on the risks of coronary herat disease, cancer and bleeding. J Hypertension 1997; 15: 105-15.
62. ROMÁN O, CUEVAS G, BUNOUT D. Influencia de factores de riesgo y terapia farmacológica en la mortalidad de hipertensos esenciales. Rev Méd Chile 1998; 126: 745-52.
63. THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD PRESSURE. The sixth report. National Institutes of Health Publication. No 98-4080. 1987.